Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 plus Histamine Dihydrochloride in Stage IV Melanoma with Liver Metastasis
NCT00039234Phase 3Unknown
- Sponsor
- Maxim Pharmaceuticals
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of histamine dihydrochloride in melanoma (2 arms), sponsored by Maxim Pharmaceuticals. Primary endpoint: Duration of Survival. Status: unknown.
02
Drugs
histamine dihydrochloride
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00039234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039234.